Hemogenyx Pharmaceuticals PLC HEMO-CAR-T Process Qualification Run Completed
January 04 2023 - 2:00AM
RNS Non-Regulatory
TIDMHEMO
Hemogenyx Pharmaceuticals PLC
04 January 2023
4 January 2023
RNS Reach - Non-Regulatory
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
HEMO-CAR-T Second Process Qualification Run Completed
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical
group developing new therapies and treatments for deadly blood
diseases, is pleased to announce the successful completion of its
second Process Qualification ("PQ") run of the end-to-end process
for the manufacture of HEMO-CAR-T cells. The process was carried
out in the Company's current Good Manufacturing Practice ("cGMP")
compliant clean rooms. It was followed by a battery of analytical
release tests required to verify the quality of the manufactured
HEMO-CAR-T cells.
This PQ run is the second of minimum three identical
manufacturing runs required for the submission of an
Investigational New Drug ("IND") application to the US Food and
Drug Administration ("FDA"). The IND is needed to obtain
authorization from the FDA to commence Phase I clinical trials of
HEMO-CAR-T.
Enquiries:
Hemogenyx Pharmaceuticals plc https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive
Officer & Co-Founder headquarters@hemogenyx.com
Peter Redmond, Director peter.redmond@hemogenyx.com
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre,
Adam Cowl
Peterhouse Capital Limited Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles
Goodfellow
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE:
HEMO) headquartered in London, with its US operating subsidiaries,
Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New
York City at its state-of-the-art research facility.
The Company is a pre-clinical stage biopharmaceutical group
developing new medicines and treatments to treat blood and
autoimmune disease and to bring the curative power of bone marrow
transplantation to a greater number of patients suffering from
otherwise incurable life-threatening diseases. Hemogenyx
Pharmaceuticals is developing several distinct and complementary
product candidates, as well as platform technologies that it uses
as engines for novel product development.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRABLGDBSDGDGXX
(END) Dow Jones Newswires
January 04, 2023 02:00 ET (07:00 GMT)
Silver Falcon (LSE:SILF)
Historical Stock Chart
From Apr 2024 to May 2024
Silver Falcon (LSE:SILF)
Historical Stock Chart
From May 2023 to May 2024